Tag archives: pharma

Strong outlook for pharma and biotech M&A in 2017

While certain sectors experienced a shaky 2016 with respect to M&A activity, deal activity in the pharmaceutical and biotechnology industries held steady following record levels in 2015 and is expected to perform equally as well in 2017. In Prognosis positive: Pharma and biotech M&A outlook, a recent report by Mergermarket (the Report) on these industries, … Continue reading

$40 billion in deals in one day: is “big pharma” getting bigger?

In a single day last week, $40 billion worth of deals were announced in the pharmaceutical industry.  The jaw-dropping, combined value of the announced mergers and acquisitions has turned heads, and has prompted analysts to question the impetus behind these deals. The increased activity may come as a surprise to some, as recent changes by … Continue reading

New Year’s resolution: buying & selling smart

2015 was a huge year for global M&A with deal activity reaching $4.2 trillion by the middle of December.  If 2016 continues at the same pace, be prepared for a big year of M&A activity. In order to be well equipped for the upcoming year, ask yourself the following two questions when contemplating an M&A … Continue reading

M&A activity in the pharmaceutical sector is driving the commercialization of new drugs

The global pharmaceutical sector has been rocked by several significant mergers and acquisitions in 2015: Indian generics firm Sun Pharma purchased GSK’s Australian opiates operations, citing the development of analgesics as a key growth opportunity US-based AbbVie acquired Pharmacyclics, with a central motivation being the acquisition of the blockbuster cancer drug Imbruvica US giant Pfizer … Continue reading

Cross-border and private equity activity in Q2 2015

As we move towards the end of the second quarter of 2015, many have wondered whether this year will be able to live up to the bumper year of 2014 in terms of cross-border private equity activity. Despite volatile commodity prices and an unsteady European market, a recent survey conducted by integrated communications firm RR Donnelley revealed … Continue reading

More and bigger: Global and North American M&A market update

The 2014 trend of high value deals continues, according to a recently released Mergermarket Monthly M&A Insider report on global M&A activity. Through the month of October, the aggregate value of deals worldwide for the year has surpassed the last year’s total. Volume, on the other hand, still has some way to go before matching … Continue reading

M&A in the pharma sector: big deals are on the uptick

According to the Q1 2014 trend report on Global Pharma, Medical & Biotech (PMB) published by MergerMarket earlier this month, PMB M&A activity totaled US $63.4 billion globally in Q1 2014, representing the second highest quarter in the sector since Q4 2010. Indeed, not only did Q1 2014 numbers represent a significant increase compared to … Continue reading

Biotech and pharma: next on the patent troll hit list?

Patent trolls, alternatively known as non-practising entities (NPEs) or patent monetizers, have been dominating discussion relating to patent reform for quite some time. For example, the White House, the FTC, Congress, individual U.S. states and the U.S. Patent and Trademark Office have each conducted their own investigations and proposed guidelines and legislation aimed at curbing … Continue reading
LexBlog